Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug834 | ColdZyme® mouth spray Wiki | 0.45 |
| drug3755 | Zinc Sulfate Wiki | 0.45 |
| drug3698 | Wait list time Wiki | 0.45 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2092 | Morning Bright Light Therapy Wiki | 0.45 |
| drug2172 | Negative Ion Generator Wiki | 0.45 |
| drug1582 | Hypothermia Wiki | 0.32 |
| drug2176 | Neuromuscular Blocking Agents Wiki | 0.32 |
| drug1434 | HCQ Wiki | 0.22 |
| drug776 | Chloroquine Wiki | 0.17 |
| drug3749 | Zinc Wiki | 0.16 |
| drug364 | Azithromycin Wiki | 0.15 |
| drug3231 | Standard of care Wiki | 0.10 |
| drug1745 | Ivermectin Wiki | 0.10 |
| drug1520 | Hydroxychloroquine Wiki | 0.04 |
| drug2505 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D015179 | Colorectal Neoplasms NIH | 0.32 |
| D007035 | Hypothermia NIH | 0.32 |
| D003139 | Common Cold NIH | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100834 | Neoplasm of the large intestine HPO | 0.32 |
Navigate: Correlations HPO
There are 5 clinical trials
This is a randomized, open-label trial to assess the safety and efficacy of hydroxychloroquine, and zinc in combination with either azithromycin or doxycycline in a higher risk COVID-19 positive outpatient population.
Description: Patients will be assessed on day 5 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial) Time: Day 5Description: Patients will be assessed on day 14 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial) Time: Day 14Description: Patients will be assessed on day 21 for when COVID-19 symptoms completely resolve compared to baseline (day 1 of trial)
Measure: Time to Resolution of Symptoms relative to baseline (day 1 of trial) Time: Day 21Description: Number of participants hospitalized and/or requiring repeat ER visits related to COVID-19 complications
Measure: Number of participants hospitalized and/or requiring repeat ER visits Time: 21 daysDescription: If hospitalized, number of participants admitted to the ICU, and number of days in the ICU
Measure: ICU Length of Stay Time: Until Discharged up to 30 daysDescription: If placed on ventilator, number of days on a ventilator
Measure: Ventilator Time: Until extubated up to 30 daysDescription: Severity of symptoms evaluated at day 5, day 14, and day 21 scored by the participant for feverishness, sore throat, cough, shortness of breath, myalgias. (0 =none; 1 = mild; 2 = moderate; 3 = severe)
Measure: Severity of symptoms Time: Day 5, Day 14, and Day 21Description: Number of participants with adverse events due to drug regimen
Measure: Number of participants with adverse events due to drug regimen Time: 21 daysDescription: Assess all patients to evaluate for QTc prolongation >500ms
Measure: Number of participants with QTc prolongation >500ms Time: Days 1 thru 5, Day 10, Day 21The aim of the study is to compare a treatment with doxycycline vs a placebo as soon as the patient is confirmed COVID-19 + and before the onset of oxygen dependence with the aim of reducing or even abolishing the cytokine explosion and thus the evolution towards a serious form of the disease which can lead to death. Three criteria support the rational use of tetrcycline in COVI-19 (1) The coronaviruses is known to bind to metalloproteases (MMPs) of the host, in particular to ensure viral survival. Tetracyclines are known to chelate zinc from MMPs. Their chelating activity may help inhibit COVID19 infection by limiting its ability to replicate in the host. (2) Tetracyclines may also be able to inhibit the replication of positive-polarity single-stranded RNA viruses, such as COVID19 (demonstrated on the dengue virus). (3) In addition, tetracyclines are modulators of innate immunity (anti-inflammatory activity), a property used in the treatment of inflammatory skin diseases for many years. These modulating effects are noted on several targets of innate immunity: They can decrease the expression of NFKB, the release of inflammatory cytokines such as TNF-α, IL-1β and IL-6, inhibit granulomas inflammatory and free radical release. Tetracyclines could therefore participate in limiting the cytokine release induced by COVID19. Their lipophilic nature and their strong pulmonary penetration could allow them to inhibit viral replication.
Description: Percentage of patients with clinical worsening (SaO2 ≤ 93%) after at least 48 hours of treatment
Measure: Percentage of Patients with Clinical Respiratory Aggravation Time: after at least 48 hours of treatmentDescription: Percentage of patients hospitalized after at least 48 hours of experimental treatment
Measure: Percentage of patients hospitalized Time: after at least 48 hours of experimental treatmentDescription: Percentage of patients requiring ventilatory assistance
Measure: Percentage of patients requiring ventilatory assistance Time: Day 0 to Day 28Description: Number of positive SARS-CoV-2 PCR tests on D-1 / D0 and D7 (+/- 2 days)
Measure: Positive SARS-CoV-2 PCR Test Time: Day -1 or day 0 AND Day 7Description: Duration of symptoms (fever, painful symptoms: headache, sore throat, dyspnea)
Measure: Duration of symptoms Time: Day 0 to Day 28Description: Total duration of hospitalization
Measure: Duration of hospitalization Time: From day 0 until to the end of hospitalization or date of death for any cause, whichever came first, assessed up to 3 months after Day0Description: Duration of hospitalization in intensive care or reanimation
Measure: Hospitalization intensive care or reanimation Time: From day 0 until to the end of hospitalization or date of death for any cause, whichever came first, assessed up to 3 months after Day0Description: Duration of mechanical ventilatory assistance
Measure: Duration of mechanical ventilatory assistance Time: to the end of mechanical ventilatory assistance if any, assessed up to 3 months after Day0Description: Percentage of deaths related to SARS-CoV-2 infection
Measure: Percentage of deaths related to SARS-CoV-2 Time: Day 28, or end of hospitalization if any (assessed up to 3 months after Day0)Description: Number of AE / SAE in both arms
Measure: AE / SAE in both arms Time: Day 28, or end of hospitalization if any (assessed up to 3 months after Day0)Efficacy of Ivermectin and Doxycycline in COVID-19 treatment
Description: The number of patients with improvement or mortality
Measure: The number of patients with improvement or mortality Time: 1 monthThe primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time blocking the development of cytokine storms or inhibiting cytokine-associated coagulopathy respectively. The investigators hypothesize that Doxycycline will will improve survival and reduce morbidity in SARS-CoV-2 infected patients. A secondary aim is to identify genetic variants that predict either an unusually mild disease or an unusually severe disease - knowledge that can be used to design new and precise medications and to be able to predict patients who might get into early trouble and to therefore hospitalize them.
Description: Days Alive and Out of Hospital (Composite Endpoint)
Measure: Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death Time: 21 daysDescription: Change From Baseline of Nasopharyngeal Luminex NxTAG CoV (Positive/Negative)
Measure: NP SARS-CoV-2 PCR Time: 21 daysDescription: Change From Baseline of SARS-CoV-2 Serum Quantitative Viral Load
Measure: SARS-CoV-2 Serum Quantitative Viral Load Time: 21 daysDescription: Change From Baseline of SARS-CoV-2 IgM/IgG Antibodies (Positive/Negative)
Measure: SARS-CoV-2 IgM/IgG Antibodies Time: 21 daysDescription: Change From Baseline of White Blood Count (CBC) K/mm3
Measure: White Blood Cell Count (WBC) Time: 21 daysDescription: Change From Baseline of Absolute Lymphocyte Count (ALC) K/mm3
Measure: Absolute Lymphocyte Count (ALC) Time: 21 daysDescription: Change From Baseline of C-Reactive Protein (CRP) mg/dL
Measure: C-Reactive Protein (CRP) Time: 21 daysDescription: Change From Baseline of N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP) pg/mL
Measure: N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP) Time: 21 daysDescription: Change From Baseline of High Sensitivity Troponin I (hsTnT) ng/mL
Measure: High Sensitivity Troponin I (hsTnT) Time: 21 daysDescription: Change From Baseline of Tumor Necrosis Factor Alpha (TNF-a)
Measure: Tumor Necrosis Factor Alpha (TNF-a) Time: 21 daysDescription: Change From Baseline of IL-1
Measure: IL-1 Time: 21 daysDescription: Change From Baseline of IL-1B
Measure: IL-1B Time: 21 daysDescription: Change From Baseline of IL-6
Measure: IL-6 Time: 21 daysEvaluation of the efficacy and safety of Treatments for Patients Hospitalized for COVID-19 Infection without signs of acute respiratory failure, in Tunisia Multicentric Randomized Comparative Study
Description: The healing criteria are defined clinically as: disappearance of clinical signs of acute respiratory infection absence of fever
Measure: Evaluate the rate of patients cured at the end of the study. Time: 2 monthsDescription: A patient will be defined as pauci-symptomatic if presence: Light dry cough Discomfort, More or less : Headache, Muscle pain
Measure: Evaluate the rate of patients are pauci-symptomatic at the end of the study. Time: 2 monthsDescription: Patients require transfer to intensive care with the appearance of: Acute respiratory failure: PaO2 <60 mmHg in AA gold Signs of circulatory insufficiency: mottling, tachycardia, systolic BP ≤90mmHg or having dropped by 40 mmHg compared to base BP or Confusion or alteration of the state of consciousness
Measure: Evaluate the rate of patients with worsening clinical signs Time: 2 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports